



# Erratum

**Erratum. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2020;43:487–493**

<https://doi.org/10.2337/dc20-er07>

*John B. Buse, Deborah J. Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A. D'Alessio, and Melanie J. Davies*

The incorrect figure legend was printed for Figure 2. The first sentence of the legend should read as follows: "Choosing glucose-lowering medication in those with indicators of high-risk or established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure (HF)."

The online version of the article (<https://doi.org/10.2337/dci19-0066>) has been updated to correct this error.